ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Duopharma Biotech Bhd's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was 13.00%.
As of today (2026-06-29), Duopharma Biotech Bhd's WACC % is 4.25%. Duopharma Biotech Bhd's ROIC % is 10.47% (calculated using TTM income statement data).
Duopharma Biotech Bhd generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Duopharma Biotech Bhd (XKLS:7148) ROIC % Explanation
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROIC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Duopharma Biotech Bhd's WACC % is 4.25%. Duopharma Biotech Bhd's ROIC % is 10.47% (calculated using TTM income statement data).
Duopharma Biotech Bhd generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Be Aware
Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duopharma Biotech Bhd ROIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's ROIC % distribution charts can be found below:
* The bar in red indicates where Duopharma Biotech Bhd's ROIC % falls into.
Note:
The Operating Income data used here is four times the quarterly (Mar. 2026) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duopharma Biotech Bhd (XKLS:7148) has a ROIC % of 13.00% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Duopharma Biotech Bhd and its competitors.
Is Duopharma Biotech Bhd's ROIC % too high?
Duopharma Biotech Bhd's current ROIC % is 13.00%. The Drug Manufacturers industry median ROIC % is 4.46. Duopharma Biotech Bhd's value of 13.00% is 191.5% above this industry median. Overall, Duopharma Biotech Bhd has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's ROIC % compare to ZTS and UTHR?
Duopharma Biotech Bhd's ROIC % of 13.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROIC % is 4.46. Duopharma Biotech Bhd's value of 13.00% is 191.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Drug Manufacturers company?
The median ROIC % among Drug Manufacturers companies is 4.46, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Duopharma Biotech Bhd's current ROIC % of 13.00% is 191.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Duopharma Biotech Bhd and its competitors. For the Drug Manufacturers industry, the median ROIC % is 4.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duopharma Biotech Bhd's current ROIC % is 13.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.52, compared to a current price of RM1.20 — trading 21.1% below its estimated fair value. The current ROIC % is 13.00% and 191.5% above the Drug Manufacturers industry median of 4.46. Duopharma Biotech Bhd's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current ROIC % is 13.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.20 is trading 21.1% below its estimated GF Value™ of RM1.52.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
ROIC %: 13.00%
GF Value™: RM1.52 vs. price of RM1.20 (21.1% below fair value)
Industry Position: 191.5% above the Drug Manufacturers median
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
83GF Score
Get the complete analysis for XKLS:7148
ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
